Literature DB >> 6696028

Results of cryotherapy for eyelid malignancies.

F T Fraunfelder, S A Zacarian, D L Wingfield, B L Limmer.   

Abstract

A total of 164 nodular and infiltrative eyelid basal cell carcinomas were treated with liquid nitrogen spray cryotherapy and followed up for a minimum of five years. For lesions less than 10 mm in diameter, nodular basal cell carcinomas had a 97% cure rate with cryotherapy and infiltrative basal cell carcinomas had a 94% cure rate. However, nodular of infiltrative basal cell carcinoma lesions larger than 10 mm in diameter had 85% and 82% cure rates with cryotherapy, respectively. After a minimum four-year follow-up period, 25 recurrent basal cell carcinomas previously treated by various methods had a 93% cure rate when re-treated with cryotherapy. Data for other malignant eyelid lesions treated with cryotherapy were insufficient for statistical analysis.

Entities:  

Mesh:

Year:  1984        PMID: 6696028     DOI: 10.1016/s0002-9394(14)76088-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  A reappraisal of cryosurgery for eyelid basal cell carcinomas.

Authors:  W Buschmann
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  Liquid nitrogen cryotherapy for surface eye disease (an AOS thesis).

Authors:  Frederick Web Fraunfelder
Journal:  Trans Am Ophthalmol Soc       Date:  2008

3.  Cis-platinum chemotherapy for ocular basal cell carcinoma.

Authors:  M Morley; P T Finger; M Perlin; L R Weiselberg; D S DeBlasio
Journal:  Br J Ophthalmol       Date:  1991-07       Impact factor: 4.638

4.  Cryotherapy for eyelid and periocular basal cell carcinomas: outcome in 166 cases over an 8-year period.

Authors:  K Tuppurainen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-04       Impact factor: 3.117

5.  Cryosurgery of Periocular Moderately Aggressive Basal Cell Carcinoma.

Authors:  Oscar Finskas; Oscar Zaar; Karin Svedberg
Journal:  Acta Derm Venereol       Date:  2020-11-26       Impact factor: 3.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.